Tykerb
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Tykerb (lapatinib; Novartis) is an orally available EGFR (epidermal growth factor receptor) and human epidermal growth factor receptor 2 (HER2) dual tyrosine kinase inhibitor. EGFR (ErbB1) and HER2 (ErbB2) form part of the ErbB family of receptor tyrosine kinases, where ligand binding ultimately results in a cascade of downstream events that regulate pathways involved in tumor growth and progression. These pathways are often amplified during tumor growth due to the overexpression of receptors and/or ligands, or because of mutation.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Tykerb : Breast cancer: HER2-positive
LIST OF FIGURES
10 Figure 1: Tykerb – SWOT analysis in HER2-positive breast cancer
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Tykerb for HER2-positive
breast cancer
11 Figure 3: Datamonitor Healthcare drug assessment summary of Tykerb for HER2-positive
breast cancer
LIST OF TABLES
4 Table 1: Tykerb (lapatinib; GlaxoSmithKline) – drug profile
7 Table 2: Overview of pivotal trial data for Tykerb in HER2-positive breast cancer
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Post-CHDI Huntington’s Disease KOL Interview 
Sign up to the